A one-time CRISPR treatment dramatically reduced attacks in hereditary angioedema, marking a major milestone for genetic medicine.
Gene editing has been generating headlines, hope and skepticism in roughly equal measure. Last weekend, it delivered something tangible: a Phase 3 clinical success.
Intellia Therapeutics announced additional positive results from its HAELO Phase 3 trial of lonvoguran ziclumeran (lonvo-z), a one-time CRISPR-based treatment for hereditary angioedema (HAE), a rare inherited disease that causes sudden and potentially life-threatening swelling attacks [1].
The findings were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 and simultaneously published in the New England Journal of Medicine.
While the treatment itself targets a rare condition, the implications reach far beyond HAE. According to Intellia, this is the world’s first positive pivotal Phase 3 clinical trial for an in vivo CRISPR gene editing therapy – meaning the gene editing occurs directly inside the patient’s body rather than in cells modified outside the body and then reinfused. For the field of genetic medicine, it represents a significant proof point that gene editing can move from scientific promise to late-stage clinical reality.
Patients who received a single dose of lonvo-z experienced an 87% reduction in average monthly HAE attacks compared with those receiving placebo during the study’s evaluation period. Perhaps even more compelling, 62% of treated patients remained completely free from attacks and did not require additional therapy during the six-month evaluation period. In the placebo group, that figure was 11%.
The newly released data added further evidence that the treatment’s impact extended beyond attack frequency. Patients experienced an 89% reduction in attacks requiring on-demand treatment and a 91% reduction in moderate-to-severe attacks.
Just as importantly, patients reported meaningful improvements in daily life. Quality-of-life scores improved by more than 17 points on average. For context, researchers consider a six-point improvement clinically meaningful.
For people living with HAE, that difference can mean fewer emergency interventions, less anxiety about when the next attack might occur and greater freedom to participate in everyday activities.
HAE affects approximately one in 50,000 people and is characterized by recurrent swelling episodes that can affect various parts of the body, including the airway. Although treatments exist, many patients require lifelong preventive therapy, often involving regular injections or ongoing medication. Breakthrough attacks can still occur despite continuous treatment.
Lonvo-z takes a fundamentally different approach. Using CRISPR technology, the therapy is designed to permanently reduce production of kallikrein, a protein that plays a central role in triggering HAE attacks. Rather than continuously suppressing symptoms, the goal is to address the biological source of the disease with a single treatment.
The latest data suggest that the effect may be durable. Researchers reported that kallikrein levels dropped rapidly after treatment, stabilized by week five, and remained steady through the latest data cutoff.
Safety data also remained encouraging. The most common side effects included infusion-related reactions, headache, fatigue, back pain and upper respiratory tract infections. Reported adverse events were mild or moderate, and no serious adverse events were observed in the treatment arm during the primary observation period.
“These are the first Phase 3 results to deliver on the much-heralded promise of in vivo CRISPR gene editing,” said Dr John Leonard, president and CEO of Intellia.
For investors and observers of the longevity and biotechnology sectors, the HAELO results provide one of the clearest demonstrations yet, that gene editing platforms can generate meaningful outcomes in large, late-stage clinical trials. The broader question facing the field has been whether scientists can safely and reliably edit them inside the human body. This study suggests the answer may be yes.
Now, longevity is often framed through lifestyle interventions, diagnostics and therapies aimed at slowing aging. However, some of the most transformative advances may come from technologies capable of correcting disease at its biological roots. The success of lonvo-z does not mean gene editing will become a universal solution for aging-related diseases overnight. Regulatory reviews remain ahead, and Intellia is targeting a potential US launch in the first half of 2027. Yet the trial offers a glimpse of a future in which chronic disease management could increasingly give way to durable, potentially one-time interventions.
For patients with hereditary angioedema, that future could mean living without the constant threat of unpredictable attacks. Meanwhile, for the longevity sector, it may represent another step toward medicine that does more than manage disease – medicine that rewrites its trajectory.
